BEXSERO 25 MCG / 0.5 ML — DIN 02417030
OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN) : 25 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN : 50 MCG / 0.5 ML · GLAXOSMITHKLINE INC · SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is BEXSERO?
BEXSERO 25 MCG / 0.5 ML contains OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN) : 25 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN : 50 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02417030, held by GLAXOSMITHKLINE INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 08-Sep-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Meningococcus B, Multicomponent Vaccine cost around the world?
Meningococcus B, Multicomponent Vaccine is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Czechia | max producer price (ex-factory) | 2 | 2 |
| Iceland | max wholesale | 1 | 1 |
3 pack listings across 3 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Meningococcus B, Multicomponent Vaccine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 25 MCG / 0.5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRAMUSCULAR |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Meningococcus B, Multicomponent Vaccine |
|---|---|
| ATC code | J07AH09 |
| AHFS class | 12:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02417030 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2417030 |
| Brand name | BEXSERO |
| Generic / active ingredient | OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN) : 25 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN : 50 MCG / 0.5 ML |
| Market authorization holder | GLAXOSMITHKLINE INC |
| Health Canada schedule | Schedule D |
| ATC code | J07AH09 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07AH |
| Current status | MARKETED |
| Status date | 08-Sep-2016 |
| Original market date | 2013-12-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC J07AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated | MENACTRA · MENQUADFI · MENVEO | 3 | 2 | Yes |
| Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen | MENOMUNE-A/C/Y/W-135 · NIMENRIX | 4 | 1 | Yes |
| Meningococcal Vaccines | MENJUGATE · MENJUGATE LIQUID · TRUMENBA | 3 | 1 | Yes |
| Meningococcus C, Purified Polysaccharides Antigen Conjugated | MENINGITEC · NEISVAC-C | 2 | 1 | Yes |
| Meningococcus B, Multicomponent Vaccine | BEXSERO | 1 | 1 | Yes |
| Meningococcus, A, C, Bivalent Purified Polysacc. Antigen | MENCEVAX AC PWS 500MCG/VIAL · MENCEVAX AC PWS 50MCG/VIAL · MENCEVAX AC PWS INJ 2500MCG/VIAL · MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A & C | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07AL | Pneumococcus, Purified Polysacc.antigen Conjugated · Pneumococcus, Purified Polysaccharides Antigen | 11 | 3 |
| J07AE | Cholera, Inactivated, Whole Cell · Cholera, Live Attenuated | 4 | 2 |
| J07AP | Typhoid, Inactivated, Whole Cell · Typhoid, Oral, Live Attenuated · Typhoid, Purified Polysaccharide Antigen | 5 | 2 |
| J07AJ | Pertussis, Inact., Whole Cell, Comb. With Toxoids · Pertussis, Inactivated, Whole Cell · Pertussis, Purified Antigen · Pertussis, Purified Antigen, Comb. With Toxoids | 7 | 1 |
| J07AM | Tetanus Toxoid · Tetanus Toxoid, Comb. With Diphtheria Toxoid | 7 | 1 |
| J07AX | Other Bacterial Vaccines | 4 | 1 |
| J07AG | Hemophilus Influenzae B Vaccines · Hemophilus Influenzae B, Combinations With Pertussis And Toxoids · Hemophilus Influenzae B, Combinations With Toxoids · Hemophilus Influenzae B, Purified Antig. Conjugated | 8 | 1 |
| J07AF | Diphtheria Toxoid | 4 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL | PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02240255 |
| DUKORAL | VIBRIO CHOLERAE INABA 48 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE INABA 6973 EL TOR BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS RECOMBINANT CHOLERA TOXIN B SUBUNIT : 1 MG | VALNEVA SWEDEN AB | MARKETED | 02247208 |
| VAXCHORA | VIBRIO CHOLERAE, STRAIN CVD 103-HGR, LIVE : 2000000000 UNIT | BAVARIAN NORDIC AS | MARKETED | 02538164 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BEXSERO called?
Also recorded in Canada as: Meningococcal Group B Vaccine (rDNA, component, adsorbed) (GLOBAL), 4CMenB (GLOBAL), Meningococcal Group B Vaccine (US), Meningococcal Group B Vaccine (UK).
The same molecule, Meningococcus B, Multicomponent Vaccine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| TRUMENBA | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.